Concepedia

Lihui Lü

LL

16

Publications

863

Citations

15

H-Index

1998

Active since

Affiliations

Teva Pharmaceuticals (United States)(Current)

University of Pennsylvania

Lihui Lü is an author at Teva Pharmaceuticals (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1998–2023

16

Publications

16

Targeted Mutagenesis of the POU-Domain Gene<i>Brn4/Pou3f4</i>Causes Developmental Defects in the Inner Ear

Deborah Phippard, Lihui Lü, Daniel Lee et al. · Journal of Neuroscience · 1999 · 190 citations · Full text

, , +20

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lü et al. · Blood · 2005 · 105 citations

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 88 citations · Full text

, , +14

CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich et al. · Molecular Cancer Therapeutics · 2011 · 68 citations

Changes in the subcellular localization of the Brn4 gene product precede mesenchymal remodeling of the otic capsule

Deborah Phippard, Ahlke Heydemann, Mark S. Lechner et al. · Hearing Research · 1998 · 67 citations · Full text

, , +21

Rows per page

1–5 of 16